On the stock market since 2019, it operates in the world of health and science. It has 601 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 41% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $57.9M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
There is growth, but not at top-of-the-class tempo.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 55% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 21% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 10% a year on average.
There is $61.2M in the vault; even if every debt were paid off, $57.9M would remain.
This stock swings about 2.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 26/100.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, SRTA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SRTA is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.